AstraZeneca to upgrade US listing in ‘knock-back for London’

AstraZeneca, the UK's largest drugmaker, has announced plans to upgrade its US listing by placing its shares directly on the New York Stock Exchange, which many see as a setback for London. While the company reassures that its headquarters will remain in Cambridge, this move highlights the ongoing challenges faced by the UK market in retaining major corporations. The decision reflects broader trends in the pharmaceutical industry and raises questions about the future of London as a financial hub.